BMS-906024: Interim Phase I data

Interim data from 25 patients with relapsed or refractory T cell ALL or T cell lymphoblastic lymphoma in an open-label, dose-escalation Phase I trial showed that once-weekly 0.6, 4 and 6 mg IV BMS-906...